<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940822-2-00054</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Advisory Committees; Notice of Meetings <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=10 g=1 f=2 --> MEETINGS:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The following advisory committee meetings are announced: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Antiviral Drugs Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . September 12 and 13, 1994, 8:30 a.m.; Holiday Inn, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open committee discussion, September 12, 1994, 8:30 a.m. to 11:30 a.m.; open public hearing, 11:30 a.m. to 12 m., unless public participation does not last that long; open committee discussion, 12 m. to 5 p.m.; open committee discussion, September 13, 1994, 8:30 a.m. to 11:30 a.m.; open public hearing, 11:30 a.m. to 12 m., unless public participation does not last that long; open committee discussion, 12 m. to 4 p.m.; Lee L. Zwanziger or Valerie Mealy, Center for Drug Evaluation and Research (HFD&hyph;9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;4695. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of acquired immune deficiency syndrome (AIDS), AIDS-related complex (ARC), and other viral, fungal, and mycobacterial infections. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before September 2, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee will discuss scientific and medical issues relevant to the validation of surrogate markers for use as criteria in regulatory decisionmaking. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Anti-Infective Drugs Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . September 23, 1994, 8 a.m.,  <!-- PJG 0012 frnewline --> Holiday Inn, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open public hearing, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 11:30 a.m.; Ermona B. McGoodwin or Mary Elizabeth Donahue, Center for Drug Evaluation and Research (HFD&hyph;9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;5455.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The Anti-Infective Drugs Advisory Committee reviews and evaluates data relating to the safety and effectiveness of marketed and investigational human drugs for use in infectious and ophthalmic disorders.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before September 16, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee will discuss surrogate markers, such as pharmacokinetic parameters and microbiological inhibitory and cidal data, and whether these parameters can be used instead of clinical efficacy data to support an alternative dosing regimen for oral metronidazole in the treatment of Trichomonas vaginalis vaginitis. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Joint Meeting of the Dermatologic Drugs and Anti-Infective Drugs Advisory Committees <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . September 23, 1994, 1 p.m.,  <!-- PJG 0012 frnewline --> conference rms. D and E , Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open public hearing, 1 p.m. to 2 p.m., unless public participation does not last that long; open committee discussion, 2 p.m. to 5 p.m.; Ermona B. McGoodwin or Valerie Mealy, Center for Drug Evaluation and Research (HFD&hyph;9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;5455.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committees <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The Dermatologic Drugs Advisory Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in the treatment of dermatologic diseases. The Anti-Infective Drugs Advisory Committee reviews and evaluates data relating to the safety and effectiveness of marketed and investigational human drugs for use in infectious and ophthalmic disorders.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before September 16, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committees will discuss the potential for development of antibiotic resistance with over-the-counter use of topical erythromycin in the treatment of acne.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Peripheral and Central Nervous System Drugs Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . September 26 and 27, 1994, 8:30 a.m., conference rms. D and E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open public hearing, September 26, 1994, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 5 p.m.; open public hearing, September 27, 1994, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 5 p.m.; Michael A. Bernstein, Center for Drug Evaluation and Research (HFD&hyph;120), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;594&hyph;2775. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in neurological diseases. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before September 19, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . On September 26, 1994, the committee will discuss the safety and effectiveness of Freedox <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (tirilazad mesylate), new drug application (NDA) 20&hyph;399, The Upjohn Co., for use in the treatment of subarachnoid hemorrhage. On September 27, 1994, the committee will discuss the safety and effectiveness of Tegretol <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (carbamazepine), NDA 18&hyph;927, Basel Pharmaceuticals, for use as an anticonvulsant in children under 6 years old. Additionally, the committee will reconsider the relative risks and benefits of Felbatol <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (felbamate), NDA 20&hyph;189, Carter-Wallace, for use in the treatment of epilepsy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> National Mammography Quality Assurance Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . September 28, 1994, 10 a.m., and  <!-- PJG 0012 frnewline --> September 29 and 30, 1994, 8:30 a.m., Gaithersburg Hilton Hotel, 620 Perry Pkwy., Gaithersburg, MD. A limited number of overnight accommodations have been reserved at the Gaithersburg Hilton Hotel. Attendees requiring overnight accommodations may contact the hotel at 301&hyph;977&hyph;8900 and reference the FDA committee meeting block. Reservations will be confirmed at the group rate based on availability. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open public hearing, September 28, 1994, 10 a.m. to 11 a.m., unless public  <!-- PJG 0012 frnewline --> participation does not last that long; open committee discussion, 11 a.m. to 5 p.m.; open committee discussion, September 29, 1994, 8:30 a.m. to 5 p.m.; open committee discussion, September 30, 1994, 8:30 a.m. to 5 p.m.; Charles K. Showalter, Center for Devices and Radiological Health (HFZ&hyph;240), Food and Drug Administration, 1901 Chapman Ave., Rockville, MD 20857, 301&hyph;594&hyph;3311. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee advises on developing appropriate quality standards and regulations for the use of mammography facilities. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before September 23, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee will discuss the draft final standards for accreditation bodies and the draft  <!-- PJG 0012 frnewline --> final standards for facilities. Specific topics to be discussed include: States as certifying bodies, mobile units, breast implant imaging, consumer complaint mechanism, and equipment other than the x-ray unit. <!-- PJG 0012 frnewline --> FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above. <!-- PJG 0012 frnewline --> The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work. <!-- PJG 0012 frnewline --> Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by  <!-- PJG 0012 frnewline --> participants. <!-- PJG 0012 frnewline --> Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting. <!-- PJG 0012 frnewline --> Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.  <!-- PJG 0012 frnewline --> The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting. <!-- PJG 0012 frnewline --> Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI&hyph;35), Food and Drug Administration, rm. 12A&hyph;16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.  <!-- PJG 0012 frnewline --> This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: August 15, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUMMARY> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Linda A. Suydam, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Interim Deputy Commissioner for Operations. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;20510 Filed 8&hyph;19&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            